Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Cerilliant
Baxter
Julphar
McKinsey
Boehringer Ingelheim
Dow
Accenture
Cantor Fitzgerald
Mallinckrodt

Generated: January 20, 2018

DrugPatentWatch Database Preview

DYANAVEL XR Drug Profile

« Back to Dashboard

Which patents cover Dyanavel Xr, and when can generic versions of Dyanavel Xr launch?

Dyanavel Xr is a drug marketed by Tris Pharma Inc and is included in one NDA. There are five patents protecting this drug.

This drug has twenty-one patent family members in fourteen countries.

The generic ingredient in DYANAVEL XR is amphetamine. There are fifty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the amphetamine profile page.

US Patents and Regulatory Information for DYANAVEL XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tris Pharma Inc DYANAVEL XR amphetamine SUSPENSION, EXTENDED RELEASE;ORAL 208147-001 Oct 19, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Tris Pharma Inc DYANAVEL XR amphetamine SUSPENSION, EXTENDED RELEASE;ORAL 208147-001 Oct 19, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Tris Pharma Inc DYANAVEL XR amphetamine SUSPENSION, EXTENDED RELEASE;ORAL 208147-001 Oct 19, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Tris Pharma Inc DYANAVEL XR amphetamine SUSPENSION, EXTENDED RELEASE;ORAL 208147-001 Oct 19, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Tris Pharma Inc DYANAVEL XR amphetamine SUSPENSION, EXTENDED RELEASE;ORAL 208147-001 Oct 19, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Tris Pharma Inc DYANAVEL XR amphetamine SUSPENSION, EXTENDED RELEASE;ORAL 208147-001 Oct 19, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for DYANAVEL XR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,198,864 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
8,202,537 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
9,675,704 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
8,337,890 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
9,522,191 Modified release formulations containing drug--ion exchange resin complexes ➤ Subscribe
8,790,700 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
8,491,935 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
9,549,989 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for DYANAVEL XR

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Farmers Insurance
Cerilliant
Argus Health
Daiichi Sankyo
Julphar
Teva
Healthtrust
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot